{
  "documentMetadata": {
    "title": "Osteomyelitis, Sternal",
    "lastUpdated": "2024-04-12",
    "sourceFile": "Osteomyelitis, Sternal.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Osteomyelitis of the sternum, post-operative."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Staphylococcus aureus",
        "Staphylococcus epidermidis",
        "Less commonly, Gram-negative bacteria"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "list",
      "items": [
        "Sternal debridement is indicated for bone culture and for removal of necrotic bone.",
        "Empiric therapy: Vancomycin 15-20 mg/kg IV q8-12h to achieve preferred target AUC24 400-600 µg/mL x hr (see vancomycin AUC dosing calculator; alternative is trough of 15-20 µg/mL) + Cefepime 1-2 gm IV q8h",
        "Confirmed methicillin-resistant staphylococcal strain: Vancomycin 15-20 mg/kg IV q8-12h to achieve preferred target AUC24 400-600 µg/mL x hr (see vancomycin AUC dosing calculator; alternative is trough of 15-20 µg/mL)",
        "Confirmed methicillin-susceptible staphylococcal strain:",
        "Nafcillin 2 gm IV q4h"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "Linezolid NAI 600 mg IV/po bid or Daptomycin 10 mg/kg IV q24h for confirmed methicillin-resistant staphylococcal strain (See Comments)",
        "Cefazolin 2 gm IV q8h for confirmed methicillin-susceptible staphylococcal stain"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Duration of therapy not well defined, but a prolonged course of therapy, e.g., 6-8 weeks, is recommended."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "For gram negative infections, select an agent based on local factors: species prevalence in surgical infections and susceptibility profiles (e.g., expanded-spectrum cephalosporins, Piperacillin-tazobactam, carbapenems)",
        "Linezolid less attractive for prolonged therapy (> 2 weeks) because of potential toxicity.",
        "A fluoroquinolone is an alternative for gram-negatives but use may be limited if there is high prevalence of resistance among Enterobacteriaceae and Pseudomonas aeruginosa.",
        "Systematic review of vacuum-assisted wound closure: J Plast Reconstr Aesthet Surg. 2023 Oct 17: S1748-6815(23)00628-9."
      ]
    }
  ]
}